Paul Tudor Jones's TMO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 8,610 shares of Thermo Fisher Scientific Inc. (TMO) worth $4.99 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in TMO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 60,023 shares. Largest reduction occurred in Q3 2025, reducing 85,253 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Thermo Fisher Scientific (TMO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Thermo Fisher Scientific (TMO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +8,610 | New Buy | 8,610 | $579.45 |
| Q3 2025 | -85,253 | Sold Out | 0 | $0.00 |
| Q2 2025 | +60,023 | Add 237.90% | 85,253 | $405.46 |
| Q1 2025 | +16,739 | Add 197.14% | 25,230 | $497.60 |
| Q4 2024 | -15,816 | Reduce 65.07% | 8,491 | $520.23 |
| Q3 2024 | -32,282 | Reduce 57.05% | 24,307 | $618.57 |
| Q2 2024 | +56,589 | New Buy | 56,589 | $553.00 |
| Q1 2024 | -26,671 | Sold Out | 0 | $0.00 |
| Q4 2023 | -31,415 | Reduce 54.08% | 26,671 | $530.79 |
| Q3 2023 | -391 | Reduce 0.67% | 58,086 | $506.17 |
| Q2 2023 | +58,477 | New Buy | 58,477 | $521.75 |
| Q4 2022 | -720 | Sold Out | 0 | $0.00 |
| Q3 2022 | -3,140 | Reduce 81.35% | 720 | $506.94 |
| Q2 2022 | +3,860 | New Buy | 3,860 | $543.26 |
| Q1 2022 | -745 | Sold Out | 0 | $0.00 |
| Q4 2021 | +745 | New Buy | 745 | $667.11 |
| Q2 2021 | -8,226 | Sold Out | 0 | $0.00 |
| Q1 2021 | +3,640 | Add 79.37% | 8,226 | $456.36 |
| Q2 2020 | +983 | Add 27.28% | 4,586 | $362.41 |
| Q1 2020 | -2,579 | Reduce 41.72% | 3,603 | $283.65 |
| Q4 2019 | +6,182 | New Buy | 6,182 | $324.81 |
| Q3 2019 | -2,993 | Sold Out | 0 | $0.00 |
| Q2 2019 | +2,993 | New Buy | 2,993 | $293.69 |
| Q1 2019 | -7,120 | Sold Out | 0 | $0.00 |
| Q4 2018 | +7,120 | New Buy | 7,120 | $223.74 |
| Q3 2018 | -5,777 | Sold Out | 0 | $0.00 |
| Q2 2018 | +5,777 | New Buy | 5,777 | $207.20 |
| Q3 2017 | -3,742 | Sold Out | 0 | $0.00 |
| Q2 2017 | -4,803 | Reduce 56.21% | 3,742 | $174.51 |
| Q1 2017 | +6,045 | Add 241.80% | 8,545 | $153.66 |
| Q4 2016 | -500 | Reduce 16.67% | 2,500 | $141.20 |
| Q3 2016 | -600 | Reduce 16.67% | 3,000 | $159.00 |
| Q2 2016 | +3,600 | New Buy | 3,600 | $147.78 |
| Q4 2015 | -5,500 | Sold Out | 0 | $0.00 |
| Q3 2015 | +5,500 | New Buy | 5,500 | $122.36 |
| Q2 2015 | -8,461 | Sold Out | 0 | $0.00 |
| Q1 2015 | +3,698 | Add 77.64% | 8,461 | $134.38 |
| Q4 2014 | +1,563 | Add 48.84% | 4,763 | $125.34 |
| Q3 2014 | -3,190 | Reduce 49.92% | 3,200 | $121.56 |
| Q2 2014 | -2,745 | Reduce 30.05% | 6,390 | $118.00 |
| Q1 2014 | +9,135 | New Buy | 9,135 | $120.20 |
| Q3 2013 | -3,900 | Sold Out | 0 | $0.00 |
| Q2 2013 | +3,901 | Add 0.00% | 3,900 | $84.62 |
Paul Tudor Jones's Thermo Fisher Scientific Investment FAQs
Paul Tudor Jones first purchased Thermo Fisher Scientific Inc. (TMO) in Q2 2013, acquiring 3,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Thermo Fisher Scientific Inc. (TMO) for 45 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Thermo Fisher Scientific Inc. (TMO) was in Q2 2025, adding 85,253 shares worth $34.57 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 8,610 shares of Thermo Fisher Scientific Inc. (TMO), valued at approximately $4.99 M.
As of the Q4 2025 filing, Thermo Fisher Scientific Inc. (TMO) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Thermo Fisher Scientific Inc. (TMO) was 85,253 shares, as reported at the end of Q2 2025.